Johnson &a; Johnson Development Corporation
Johnson &a; Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Business Model: B2C B2B
Revenue: $16.3M
Employees: 2-10
Rankings
Detailed Johnson &a; Johnson Development Corporation Information
Geographic Data
Address: 410 George St
City: New Brunswick
State: NJ
Zip: 08901
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Johnson &a; Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson &a; Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson &a; Johnson. JJDC plays an integral role in the identification of new business opportunities outside of Johnson &a; Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson &a; Johnson operating companies.
Contact Phone:
+17325243214
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2007 | Axial Biotech | Series B | 15.3M |
| 3/2000 | InfoMedics | Venture Round | 6M |
| 1/2014 | PowerVision | Series D | 0 |
| 12/2005 | Light Sciences Oncology | Series A | 32M |
| 3/2009 | GetWellNetwork | Series C | 10M |
| 4/2013 | ReVision Optics | Equity | 15M |
| 3/2000 | Cyrano Sciences | Venture Round | 23M |
| 11/2011 | Biocartis | Series C | 95.8M |
| 7/2006 | InSound Medical | Series E | 18.9M |
| 4/2001 | Vascular Architects | Series C | 20M |
| 9/2014 | Inivata | Venture Round | 6.6M |
| 11/2009 | Spinal Modulation | Series C | 27.4M |
| 10/2009 | Direct Flow Medical | Series C | 40M |
| 2/2008 | InSound Medical | Series E | 11M |
| 3/2022 | Osteal Therapeutics | Series B | 0 |
| 11/2013 | Pulmocide | Series A | 27.6M |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 1/2002 | Sleep Solutions | Series E | 7M |
| 10/2007 | Optherion | Series A | 37M |
| 1/2009 | Acclarent | Venture Round | 26M |
| 10/2009 | Sleep Solutions | Series F | 20M |
| 10/2003 | Sleep Solutions | Venture Round | 6.1M |
| 5/2000 | Sleep Solutions | Series C | 3M |
| 2/2013 | OptiScan Biomedical | Private Equity Round | 30.7M |
| 2/2009 | ImaCor | Series A | 0 |
| 8/2009 | Neurosearch | Venture Round | 14.3M |
| 6/2010 | Aquinox Pharmaceuticals | Series B | 0 |
| 9/2012 | Catalyst Biosciences | Post-IPO Equity | 13.4M |
| 2/2016 | Cala Health | Series B | 0 |
| 12/2014 | Padlock Therapeutics | Series A | 23M |
| 4/2010 | Biocartis | Series B | 40M |
| 9/2014 | Biocartis | Series F | 0 |
| 4/2002 | Replidyne | Series A | 13M |
| 1/2011 | 23andMe | Series C | 9M |
| 1/2012 | PowerVision | Series C | 12.5M |
| 9/2002 | KuDOS Pharmaceuticals Ltd | Series C | 45.2M |
| 10/2008 | Biolex Therapeutics | Series D | 0 |
| 1/2005 | Biolex Therapeutics | Venture Round | 8M |
| 6/2001 | NitroMed | Series E | 0 |
| 9/2004 | Vascular Architects | Series E | 0 |
| 5/2002 | eNeura Therapeutics | Series A | 1M |
| 8/2005 | 7TM Pharma | Venture Round | - |
| 7/2013 | CVRx | Series F | 0 |
| 6/2012 | PhaseBio Pharmaceuticals | Series B | 23M |
| 6/2007 | Aquinox Pharmaceuticals | Series A | 14.5M |
| 1/2009 | 7TM Pharma | Venture Round | 0 |
| 3/2005 | TorreyPines Therapeutics | Series C | 0 |
| 5/2007 | CVRx | Series D | 65M |
| 11/2009 | Celladon | Series C | 21.8M |
| 2/2012 | Celladon | Venture Round | 43M |
| 12/2012 | Biocartis | Series D | 0 |
| 1/2006 | Archus Orthopedics | Series C | 35M |
| 6/2009 | Pronota | Series B | 7.4M |
| 8/2003 | Biolex Therapeutics | Venture Round | 0 |
| 6/2013 | Protagonist Therapeutics | Series B | 0 |
| 6/2013 | Vedanta Biosciences | Venture Round | - |
| 3/2004 | InSound Medical | Series D | 17.2M |
| 11/2001 | Locus Pharmaceuticals | Series C | 0 |
| 11/2000 | Locus Pharmaceuticals | Series B | 0 |
| 3/2011 | Astute Medical | Series B | 13M |
| 5/2000 | Global Telemedix | Series B | 0 |
| 5/2010 | Breathe Technologies | Series C | 23M |
| 8/2008 | Neuron Systems | Series A | 9M |
| 11/2010 | 23andMe | Series C | 22.2M |
| 9/2009 | NovoCure | Venture Round | - |
| 5/2010 | Astute Medical | Series B | 26.5M |
| 8/2004 | Othera Pharmaceuticals | Series B | 0 |
| 6/2007 | 7TM Pharma | Series D | 22M |
| 3/2017 | Grail | Series B | 0 |
| 1/2012 | Pronota | Series C | 4.8M |
| 3/2006 | 7TM Pharma | Series C | 0 |
| 9/2009 | Neotract | Series B | 28.1M |
| 10/2010 | Intio | Series B | 8.1M |
| 5/2012 | Mitralign | Series D | 0 |
| 4/2006 | Pronota | Series A | 7.8M |
| 7/2013 | ViaCyte | Series C | 10.6M |
| 10/2003 | OmniSonics Medical Technologies | Series C | 43M |
| 6/2011 | Spinal Modulation | Series D | 0 |
| 11/2003 | CardioMEMS | Series B | 0 |
| 1/2004 | Animas Corporation | Venture Round | 16.9M |
| 1/2003 | Vascular Architects | Series D | 0 |
| 5/2006 | ViaCyte | Venture Round | 0 |
| 5/2021 | Binx Health | Series E | 0 |
| 3/2003 | Sopherion Therapeutics | Series A | 0 |
| 7/2004 | Intrapace | Series C | 0 |
| 1/2010 | PhaseBio Pharmaceuticals | Series B | 25M |
| 7/2005 | Ilypsa | Series B | 36M |
| 7/2000 | Lumenos | Series B | 34M |
| 12/2000 | InfoMedics | Venture Round | 10M |
| 5/2009 | iScience Interventional | Series F | 20.5M |
| 2/2014 | Thesan Pharmaceuticals | Series B | 49M |
| 11/2010 | Syntaxin | Series C | 29M |
| 12/2007 | Mitralign | Series C | 0 |
| 10/2004 | Acuity Pharmaceuticals | Series B | 0 |
| 7/2008 | CVRx | Series E | 0 |
| 1/2008 | Arbor Surgical Technologies | Series C | 0 |
| 4/2013 | Aquinox Pharmaceuticals | Series C | 0 |
| 6/2014 | Aduro BioTech | Series C | 55.7M |
| 6/2003 | Orqis Medical | Series C | 25M |
| 10/2007 | Direct Flow Medical | Series B | 27M |
| 9/2002 | CellGate | Series D | 10M |
| 5/2005 | Mazor Robotics | Series B | 10M |
| 7/2007 | ViaCyte | Series C | 0 |
| 7/2002 | Transvascular | Series D | 10.8M |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 11/2013 | Biocartis | Series E | 0 |
| 1/2011 | Zeo | Series C | 0 |
| 3/2004 | BioRexis | Series B | 30M |
| 7/2013 | ReVision Optics | Series E | 55M |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 12/2000 | Sleep Solutions | Series D | 8M |
| 10/2007 | Syntaxin | Series B | 32M |
| 6/2014 | Navitor Pharmaceuticals | Series A | 23.5M |
| 6/2013 | Rodin Therapeutics | Seed Round | - |
| 5/2014 | Rodin Therapeutics | Series A | 12.9M |
| 10/2007 | Tengion | Series C | 33M |
| 6/2009 | CoAxia | Series D | 21.5M |
| 6/2006 | Tengion | Series B | 50M |
| 7/2003 | InSound Medical | Series D | 6.5M |
| 1/2012 | iScience Interventional | Venture Round | 2.8M |
| 10/2003 | Critical Therapeutics,Inc. | Series B | 56M |
| 8/2011 | NeuroPace | Venture Round | 0 |
| 7/2013 | NeuroPace | Venture Round | 18M |
| 1/2015 | Willow | Series A | 15M |
| 6/2000 | iKnowMed | Series C | 30.7M |
| 11/2016 | ReVision Optics | Venture Round | 32M |
| 10/2007 | PhaseBio Pharmaceuticals | Venture Round | 6.6M |
| 12/2009 | Genocea Biosciences | Series B | 25.7M |
| 10/2005 | Light Sciences Oncology | Series A | 35M |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 10/2012 | Genocea Biosciences | Series C | 30M |
| 8/2005 | Tengion | Series A | 39M |
| 7/2011 | Nevro | Series B | 58M |
| 7/2011 | Binx Health | Series B | 27.1M |
| 10/2013 | Merus | Series B | 42.2M |
| 3/2013 | CoStim Pharmaceuticals | Series A | 22M |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 1/2011 | Genocea Biosciences | Series B | 35M |
| 4/2007 | CymaBay Therapeutics | Series D | 32M |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 8/2007 | Molecular Partners | Series A | 15.6M |
| 12/2009 | Molecular Partners | Series B | 44.2M |
| 3/2009 | GI Dynamics | Series C | 0 |
| 9/2005 | Biolex Therapeutics | Series B | 36M |
| 5/2007 | Biolex Therapeutics | Series C | 30M |
| 8/2008 | Brainsgate | Series C | 27.5M |
| 3/2013 | Nevro | Series C | 0 |
| 4/2012 | Direct Flow Medical | Venture Round | 0 |
| 4/2014 | Binx Health | Series B | 0 |
| 11/2004 | Corthera | Series B | 15M |
| 5/2014 | Inspire Medical Systems | Series E | 0 |
| 7/2004 | Accumetrics | Series B | 0 |
| 8/2019 | CVRx | Series G | 93M |
| 11/2014 | La Lumiere | Series B | 20M |
| 7/2003 | Immunicon | Series F | 24.8M |
| 3/2007 | Orqis Medical | Series D | 12M |
| 1/2014 | TopiVert | Venture Round | 7.4M |
| 3/2022 | Osteal Therapeutics | Series B | 0 |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 8/2019 | CVRx | Series G | 0 |
| 3/2017 | Grail | Series B | 0 |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 11/2016 | ReVision Optics | Venture Round | 0 |
| 2/2016 | Cala Health | Series B | 0 |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 1/2015 | Willow | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
